MBX Biosciences (NASDAQ: MBX) experienced a significant stock surge of 139.10% in premarket trading after announcing positive results from its Phase 2 trial for canvuparatide. The trial demonstrated that 63% of patients achieved the primary endpoint at 12 weeks, compared to 31% in the placebo group. Following these promising results, MBX Biosciences plans to proceed to Phase 3 development in 2026.